Racura links bisantrene’s active isomer to MYC gene silencing
Racura Oncology has presented preclinical data identifying (E,E)-bisantrene as the major active isomer responsible for stabilizing the MYC G-quadruplex and reducing MYC gene expression. The company said the findings support development of RC220 and its EMILI, HARNESS and CPACS clinical programs.
- (E,E)-bisantrene was identified as the major active isomer in the study.
- Blue light converted the compound into less active isomers.
- Pure (E,E)-bisantrene reduced MYC expression in MDA-MB-231 cells.
- Racura says the findings support RC220 and three clinical programs.
Data presented at Singapore cancer conference
Racura Oncology Limited said on November 12 that its scientists and collaborators at the University of Wollongong, Australia, are presenting the data in a poster at the Frontiers in Cancer Science 2026 Conference in Singapore, held from 11, 13 November 2026.
The poster, titled Light-Induced Isomerization Attenuates (E,E)-Bisantrene G-Quadruplex Binding and MYC Silencing, examines how different molecular forms of bisantrene affect the compound’s activity against MYC. Racura describes (E,E)-bisantrene as the major active isomer able to stabilize the G-quadruplex in the MYC gene promoter region, leading to lower MYC gene expression and MYC protein levels.
Light exposure reduced the compound’s activity
In the preclinical study, blue light at 440 nm converted (E,E)-bisantrene into less active isomers. The compound’s content in solution fell to approximately 60% after 15 minutes, approximately 40% after one hour and an unquantifiable level after four hours.
In MDA-MB-231 breast cancer cells, pure (E,E)-bisantrene suppressed MYC gene expression with a half-maximal effective concentration of 277 nM. The corresponding range for light-exposed isomer mixtures was 514 nM to 1,166 nM. Pure (E,E)-bisantrene reduced cancer cell viability with a half-maximal inhibitory concentration of 266 nM, compared with 310 nM to 825 nM for the mixtures.
An isomer mixture containing 62% (E,E)-bisantrene stabilized the MYC G-quadruplex significantly less than pure (E,E)-bisantrene at the same concentration. Stabilization returned when the amount of (E,E)-bisantrene was matched, according to the company.
Implications for RC220 development
Racura is developing RC220 as a proprietary formulation of (E,E)-bisantrene. The company says RC220 is designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion.
Racura is investigating RC220’s MYC-directed mechanism through an ongoing research collaboration with Purdue University. Its clinical programs include the EMILI Phase 2b/3 trial in acute myeloid leukemia, the HARNESS Phase 1 trial with osimertinib in mutant epidermal growth factor receptor non-small cell lung cancer, and the CPACS Phase 1 trial with doxorubicin.
Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, said the findings “support our development of RC220 as a proprietary formulation of (E,E)-bisantrene.” Racura also cautioned that the results are preclinical, meaning they add evidence for the proposed mechanism but do not establish clinical outcomes.

